Maël Heiblig

24PUBLICATIONS
295CO-AUTHORS
Gene and molecular therapyMedical infection agents (incl. prions)PharmacogenomicsAutoimmunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

|Feb 27, 2026
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.

David B Beck, Maël Heiblig, Sinisa Savic

|Nov 27, 2025
Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors.

Romain Stammler, Peter Chen, Orianne Debeaupuis

|Nov 25, 2025
Establishing a consensus definition of VEXAS flare for clinical research.

Lachelle D Weeks, Danielle Hammond, Sinisa Savic

|Sep 25, 2025
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Eunice S Wang, Pau Montesinos, James Foran

Pageof 4

Frequent Collaborators

6 joint publications

Arsene Mekininan

5 joint publications

Thibault Comont

4 joint publications

Sophie Georgin-Lavialle

4 joint publications

Emmanuelle Tavernier-Tardy